Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of salvianolic acid A in preparation of anti-cerebral hemorrhage drug

A salvianolic acid and drug technology, which is applied in the application field of salvianolic acid A in the preparation of anti-cerebral hemorrhage drugs, can solve the problems that there are no reports on the application of salvianolic acid A anti-cerebral hemorrhage drugs, and achieve significant blood-brain barrier protection. The effect of inhibiting blood-brain barrier damage and reducing the risk of HT

Pending Publication Date: 2020-05-01
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no application report of salvianolic acid A in the preparation of anti-cerebral hemorrhage drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of salvianolic acid A in preparation of anti-cerebral hemorrhage drug
  • Application of salvianolic acid A in preparation of anti-cerebral hemorrhage drug
  • Application of salvianolic acid A in preparation of anti-cerebral hemorrhage drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1. Salvianolic acid A reduces brain damage caused by delayed administration of t-PA in rat intravascular thrombus formation acute stroke model

[0041] infarct volume.

[0042] Experimental materials: Sprague Dawley (SD) rats were purchased from Weitong Lihua (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.). t-PA was purchased from Boehringer-Ingelheim, Germany. Salvianolic acid A powder was provided by the National Center for Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences. Physiological saline for injection (Shijiazhuang Pharmaceutical No. 4 Factory) was added during injection, and used according to doses of 5, 10, and 20 mg / kg. SD rats with a body weight ranging from 250 to 300 g were anesthetized by intraperitoneal injection of chloral hydrate (350 mg / kg). The hair around the bregma was shaved, and the skin on the top of the head was cut to expose the bregma. Select 2 mm behind bregma and 5 mm to the right...

Embodiment 2

[0048] Example 2. Salvianolic acid A reduces cerebral edema caused by delayed administration of t-PA in rat intravascular thrombosis acute stroke model

[0049] Animal modeling and administration methods are the same as in Example 1. After 24 hours of ischemia, the brain tissue was weighed to measure the wet weight and dry weight, and the water content of the brain was calculated by the wet and dry weight method, which reflected the severity of cerebral edema.

[0050] The result is as figure 2 As shown, brain water content significantly increased after ischemia and t-PA administration, salvianolic acid A dose-dependent reduction of brain water content, wherein the 20mg / kg group compared with t-PA group had a statistical difference.

[0051] Effect of t-PA thrombolytic therapy on cerebral infarct volume. # P<0.05, n=5 compared with t-PA group.

[0052] Table 2. The effect of salvianolic acid A on cerebral edema after t-PA thrombolytic therapy was delayed for 6 hours in the...

Embodiment 3

[0054] Example 3. Salvianolic acid A improves nerve function damage caused by delayed administration of t-PA in rat intravascular thrombus formation acute stroke model.

[0055] Animal modeling and administration methods are the same as in Example 1. After 24 hours of ischemia, neurological score, rotarod test, suspension test and inclined plate test were used to evaluate the neurological damage of the rats.

[0056] The result is as image 3 As shown, each group of salvianolic acid A has a certain effect on neurological function, and the 20mg / kg group has a statistical difference compared with the t-PA group in the neurological score and rotarod test.

[0057] Table 3. Effects of salvianolic acid A on neurological function after t-PA thrombolytic therapy delayed 6 hours in the acute stroke model of intravascular thrombus formation in rats.

[0058]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of salvianolic acid A in preparation of a drug for treating cerebral hemorrhage. Cerebral hemorrhage comprises simple cerebral hemorrhage stroke, hemorrhage after cerebral embolism and hemorrhage caused by thrombolytic drug treatment and other factors. Experimental research finds that salvianolic acid A can significantly reduce the cerebral infarction volume andencephaledema of rats, improve neurological functions and protect blood-brain barrier damage caused by thrombolytic drugs such as t-PA, thereby reducing the risk and degree of hemorrhagic transformation when the thrombolytic drugs are used. The salvianolic acid A can be used for preparing the drug for treating cerebral hemorrhage and hemorrhage caused by thrombolytic drug treatment, relieving secondary hemorrhage in ischemic areas and improving prognosis of patients.

Description

technical field [0001] The present invention relates to the new application of salvianolic acid A compound in medicine preparation, mainly relates to the application of salvianolic acid A in the preparation and treatment of hemorrhagic stroke and cerebral hemorrhage side effects caused by thrombolytic drugs, especially relates to the application of salvianolic acid A in the preparation of Hemorrhagic transformation after the onset of cerebral embolism and the application of drugs in cerebrovascular accidents caused by thrombolytic drugs. Background technique [0002] Cerebral embolism refers to the blockage of cerebral blood vessels due to various factors such as various emboli in the blood (such as wall thrombus in the heart, atherosclerotic plaque, etc.) entering the cerebral arteries with the blood flow. When it cannot compensate, it will cause ischemic necrosis of the brain tissue in the arterial blood supply area, and then focal neurological deficits will appear. One o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61P9/10A61P7/02
CPCA61K31/216A61P9/10A61P7/02
Inventor 杜冠华孔令雷陈燕霞张莉王海港马寅仲
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com